{"success":true,"data":{"pressRelease":{"id":"52928","rtpr_id":"nGNXbsWh7g","ticker":"NANOB","exchange":"Euronext Paris","all_tickers":["NANOB"],"title":"Nanobiotix Provides First Quarter 2026 Operational and Financial Update","author":"Globe Newswire","published_at":"2026-06-02T20:30:00.258Z","article_body":"* Completed a follow-on offering in May 2026 for aggregate gross proceeds of\napproximately €86.1 million, including issuance of pre-funded warrants to\naccelerate the development of Company’s other platforms\n* New data from Part 1 of the J&J sponsored Phase 2 CONVERGE study, evaluating\nJNJ-1900 (NBTXR3) for patients with Stage 3 inoperable non-small cell lung\ncancer (NSCLC), presented at the 2026 annual European Society for Radiotherapy\nand Oncology (ESTRO)\n* Announced FDA acceptance of a protocol amendment to ongoing pivotal J&J\nsponsored NANORAY-312 study eliminating the previously planned interim\nanalysis and modifying the final analysis to include fewer events and to be\nconducted sooner\n* Presented new preclinical data evaluating its Nanoprimer platform in\nsequence with lipid nanoparticle-delivered recombinant DNA at the 2026 Annual\nMeeting of the American Association for Cancer Research (AACR)\n* €42.1 million in cash and cash equivalents as of March 31, 2026\nPARIS and CAMBRIDGE, Mass., June 02, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX\n(https://www.globenewswire.com/Tracker?data=3_u4QNy6yvm5c8MXF869h_PvH_NLG63KXKuH4TA8yKLpXbDwxm74KR2IU8WuNBEADTg5IkaRRtgRWD1khFN6aw==)\n(Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-clinical stage\nbiotechnology company pioneering nanotherapeutic approaches to expand\ntreatment possibilities for patients with cancer and other major diseases,\ntoday provided an update on operational progress and reported financial\nresults for the first quarter of 2026.\n\n“Nanobiotix continues to advance with focus, discipline, and ambition as we\nwork to unlock the full potential of physics-based nanotherapeutics,” said\nLaurent Levy, chief executive officer of Nanobiotix and chairman of the\nexecutive board. “During the first quarter of 2026, we strengthened our\nfoundation by supporting the advancement of JNJ-1900 (NBTXR3), progressing our\nNanoprimer platform, and reinforcing our financial position. We remain deeply\ngrateful to the team members, patients, investigators, collaborators and\nshareholders who give us their trust, commitment and support as we pursue our\nmission of revolutionizing treatment outcomes for millions.”\n\nOperational Highlights\n* Part 1 data from Phase 2 JNJ-1900 (NBTXR3) Study in Unresectable Stage 3\nNSCLC (CONVERGE) presented at ELCC 2026 and updated at ESTRO 2026 * Initial\ninvestigator-reported efficacy responses observed in 7 patients following the\nfull treatment regimen of concurrent chemoradiotherapy, JNJ-1900 (NBTXR3), and\nconsolidation with durvalumab showed: * Overall response rate (“ORR”) =\n85.7% (6/7 patients) reported at ESTRO 2026 * In the same cohort of 7\npatients, ORR observed at earlier time point and reported at ELCC 2026 was\n71.4% (5/7 patients)\n \n* Complete response rate (“CRR”) = 57.1% (4/7 patients) reported at ESTRO\n2026 * With the current standard of care, concurrent chemoradiation therapy\n(cCRT) ± durvalumab, depth of response remains limited in Stage 3 Inoperable\nNSCLC with very low rates of complete response (<5%)(1)\n \n* Absence of progressive disease and deepening response over time suggests\npotential for long-term durability\n* The procedure demonstrated an acceptable safety profile without serious\ntreatment-emergent adverse events (TEAEs)\n \n* Early results suggest that intratumoral/intranodal injection of JNJ-1900\n(NBTXR3) is feasible and can be performed safely in patients with stage III\nunresectable NSCLC\n \n* Protocol amendment to global Phase 3 JNJ-1900 (NBTXR3) Study in\nCisplatin-ineligible Head and Neck Cancer (NANORAY-312) * Interim analysis\neliminated and final analysis modified to be conducted sooner with fewer\nevents than originally planned\n \n* New preclinical data presented at 2026 AACR Meeting: * Pre-treatment with\nNanoprimer followed by administration of LNP-delivered recombinant DNA\n(“LNP-DNA”) designed for anti-tumor immunotherapy showed increased\nsystemic bioavailability, reduced hepatic toxicity, and reduced cGAS-STING\nrelated inflammation compared to LNP-DNA administered without the Nanoprimer\nFirst Quarter Financial Updates\n\nCash and Cash Equivalents: The Company believes that the net proceeds from the\nrecent follow-on offering, together with its cash and cash equivalents of\n€42.1 million as of March 31, 2026, will be sufficient to meet its working\ncapital requirements for operations into 2029, consistent with the Company’s\ncurrently contemplated cash burn rate.\n\nAbout JNJ-1900 (NBTXR3)\n\nJNJ-1900 (NBTXR3) is a novel, potentially first-in-class oncology product\ncomposed of functionalized hafnium oxide nanoparticles that is administered\nvia one-time intratumoral injection and activated by radiotherapy. Its\nproof-of-concept was achieved in soft tissue sarcomas through a successful\nrandomized Phase 2/3 study in 2018. The product candidate’s mechanism of\naction (MoA) is designed to induce significant tumor cell death in the\ninjected tumor when activated by radiotherapy, subsequently triggering\nadaptive immune response and long-term anti-cancer memory. Given the physical\nMoA, Nanobiotix believes that JNJ-1900 (NBTXR3) could be scalable across any\nsolid tumor that can be treated with radiotherapy and across any therapeutic\ncombination, particularly immune checkpoint inhibitors.\n\nRadiotherapy-activated JNJ-1900 (NBTXR3) is being evaluated across multiple\nsolid tumor indications as a single agent or combination therapy. The program\nis led by NANORAY-312—a global, randomized Phase 3 study in locally advanced\nhead and neck squamous cell cancers. In February 2020, the United States Food\nand Drug Administration granted regulatory Fast Track designation for the\ninvestigation of JNJ-1900 (NBTXR3) activated by radiation therapy, with or\nwithout cetuximab, for the treatment of patients with locally advanced HNSCC\nwho are not eligible for platinum-based chemotherapy—the same population\nbeing evaluated in the Phase 3 study.\n\nGiven the Company’s focus areas, and balanced against the scalable potential\nof NBTXR3, Nanobiotix has engaged in a collaboration strategy to expand\ndevelopment of the product candidate in parallel with its priority development\npathways. Pursuant to this strategy, in 2019 Nanobiotix entered into a broad,\ncomprehensive clinical research collaboration with The University of Texas MD\nAnderson Cancer Center to sponsor several Phase 1 and Phase 2 studies\nevaluating JNJ-1900 (NBTXR3) across tumor types and therapeutic combinations.\nIn 2023, Nanobiotix announced a license agreement for the global\nco-development and commercialization of JNJ-1900 (NBTXR3) with Janssen\nPharmaceutica NV, a Johnson & Johnson company.\n\nAbout NANOBIOTIX\n\nNanobiotix is a late-stage clinical biotechnology company pioneering\ndisruptive, physics-based therapeutic approaches to revolutionize treatment\noutcomes for millions of patients; supported by people committed to making a\ndifference for humanity. The Company’s philosophy is rooted in the concept\nof pushing past the boundaries of what is known to expand possibilities for\nhuman life.\n\nIncorporated in 2003, Nanobiotix is headquartered in Paris, France and is\nlisted on Euronext Paris since 2012 and on the Nasdaq Global Select Market in\nNew York City since December 2020. The Company has subsidiaries in Cambridge,\nMassachusetts (United States) amongst other locations.\n\nNanobiotix is the owner of more than 30 umbrella patents associated with three\n(3) nanotechnology platforms with applications in 1) oncology; 2)\nbioavailability and biodistribution; and 3) disorders of the central nervous\nsystem.\n\nFor more information about Nanobiotix, visit us at www.nanobiotix.com or\nfollow us on LinkedIn and Twitter.\n\nDisclaimer\n\nThis press release contains “forward-looking” statements within the\nmeaning of the “safe harbor” provisions of the Private Securities\nLitigation Reform Act of 1995, including, but not limited to, statements\nregarding the use of proceed therefrom, and the period of time through which\nthe Company’s anticipates its financial resources will be adequate to\nsupport operations. Words such as “expects”, “intends”, “can”,\n“could”, “may”, “might”, “plan”, “potential”, “should”\nand “will” or the negative of these and similar expressions are intended\nto identify forward-looking statements. These forward-looking statements which\nare based on the Company’ management’s current expectations and\nassumptions and on information currently available to management. These\nforward-looking statements involve known and unknown risks, uncertainties and\nother factors that could cause actual results to differ materially from those\nimplied by the forward-looking statements, including risks related to\nNanobiotix’s business and financial performance, which include the risk that\nassumptions underlying the Company’s cash runway projections are not\nrealized. Further information on the risk factors that may affect company\nbusiness and financial performance is included in Nanobiotix’s Annual Report\non Form 20-F filed with the SEC on March 31, 2026 under “Item 3.D. Risk\nFactors”, in Nanobiotix’s 2025 universal registration document filed with\nthe AMF on March 31, 2026 under “chapter 1.5 Risk Factors”, and subsequent\nfilings Nanobiotix makes with the SEC and AMF from time to time, which are\navailable on the SEC’s website at www.sec.gov and on the AMF's website at\nwww.amf.org, The forward-looking statements included in this press release\nspeak only as of the date of this press release, and except as required by\nlaw, Nanobiotix assumes no obligation to update these forward-looking\nstatements publicly.\n\n Nanobiotix                                                                                                                                                                                                                                                                                                              \n Communications Department Brandon Owens VP, Communications +1 (617) 852-4835 contact@nanobiotix.com  Investor Relations Department Joanne Choi VP, Investor Relations (US) +1 (713) 609-3150 joanne.choi@nanobiotix.com  Ricky Bhajun Director, Investor Relations (EU) +33 (0) 79 97 29 99 investors@nanobiotix.com    \n Media Relations                                                                                                                                                                                                                                                                                                         \n France – HARDY Caroline Hardy +33 06 70 33 49 50 carolinehardy@outlook.fr                            Global – uncapped Becky Lauer +1 (646) 286-0057 uncappednanobiotix@uncappedcommunications.com                                                                                                                      \n                                                                                                                                                                                                                                                                                                                         \n\n(__________________________1) Antonia SJ, et al. N Engl J Med. 2017.\n\nAttachment\n*     2026-06-02 -- NBTX -- 1Q26 Financial Results -- FINAL\n(https://ml.globenewswire.com/Resource/Download/9b445891-f837-499e-b743-ee1303bca1a5)\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/36fb7b98-27d7-46cb-b989-fa31626657b8)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNXbsWh7g","title":"Nanobiotix Provides First Quarter 2026 Operational and Financial Update","author":"Globe Newswire","ticker":"NANOB","created":"2026-06-02T20:30:00.258Z","tickers":["NANOB"],"exchange":"Euronext Paris","article_body":"* Completed a follow-on offering in May 2026 for aggregate gross proceeds of\napproximately €86.1 million, including issuance of pre-funded warrants to\naccelerate the development of Company’s other platforms\n* New data from Part 1 of the J&J sponsored Phase 2 CONVERGE study, evaluating\nJNJ-1900 (NBTXR3) for patients with Stage 3 inoperable non-small cell lung\ncancer (NSCLC), presented at the 2026 annual European Society for Radiotherapy\nand Oncology (ESTRO)\n* Announced FDA acceptance of a protocol amendment to ongoing pivotal J&J\nsponsored NANORAY-312 study eliminating the previously planned interim\nanalysis and modifying the final analysis to include fewer events and to be\nconducted sooner\n* Presented new preclinical data evaluating its Nanoprimer platform in\nsequence with lipid nanoparticle-delivered recombinant DNA at the 2026 Annual\nMeeting of the American Association for Cancer Research (AACR)\n* €42.1 million in cash and cash equivalents as of March 31, 2026\nPARIS and CAMBRIDGE, Mass., June 02, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX\n(https://www.globenewswire.com/Tracker?data=3_u4QNy6yvm5c8MXF869h_PvH_NLG63KXKuH4TA8yKLpXbDwxm74KR2IU8WuNBEADTg5IkaRRtgRWD1khFN6aw==)\n(Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-clinical stage\nbiotechnology company pioneering nanotherapeutic approaches to expand\ntreatment possibilities for patients with cancer and other major diseases,\ntoday provided an update on operational progress and reported financial\nresults for the first quarter of 2026.\n\n“Nanobiotix continues to advance with focus, discipline, and ambition as we\nwork to unlock the full potential of physics-based nanotherapeutics,” said\nLaurent Levy, chief executive officer of Nanobiotix and chairman of the\nexecutive board. “During the first quarter of 2026, we strengthened our\nfoundation by supporting the advancement of JNJ-1900 (NBTXR3), progressing our\nNanoprimer platform, and reinforcing our financial position. We remain deeply\ngrateful to the team members, patients, investigators, collaborators and\nshareholders who give us their trust, commitment and support as we pursue our\nmission of revolutionizing treatment outcomes for millions.”\n\nOperational Highlights\n* Part 1 data from Phase 2 JNJ-1900 (NBTXR3) Study in Unresectable Stage 3\nNSCLC (CONVERGE) presented at ELCC 2026 and updated at ESTRO 2026 * Initial\ninvestigator-reported efficacy responses observed in 7 patients following the\nfull treatment regimen of concurrent chemoradiotherapy, JNJ-1900 (NBTXR3), and\nconsolidation with durvalumab showed: * Overall response rate (“ORR”) =\n85.7% (6/7 patients) reported at ESTRO 2026 * In the same cohort of 7\npatients, ORR observed at earlier time point and reported at ELCC 2026 was\n71.4% (5/7 patients)\n \n* Complete response rate (“CRR”) = 57.1% (4/7 patients) reported at ESTRO\n2026 * With the current standard of care, concurrent chemoradiation therapy\n(cCRT) ± durvalumab, depth of response remains limited in Stage 3 Inoperable\nNSCLC with very low rates of complete response (<5%)(1)\n \n* Absence of progressive disease and deepening response over time suggests\npotential for long-term durability\n* The procedure demonstrated an acceptable safety profile without serious\ntreatment-emergent adverse events (TEAEs)\n \n* Early results suggest that intratumoral/intranodal injection of JNJ-1900\n(NBTXR3) is feasible and can be performed safely in patients with stage III\nunresectable NSCLC\n \n* Protocol amendment to global Phase 3 JNJ-1900 (NBTXR3) Study in\nCisplatin-ineligible Head and Neck Cancer (NANORAY-312) * Interim analysis\neliminated and final analysis modified to be conducted sooner with fewer\nevents than originally planned\n \n* New preclinical data presented at 2026 AACR Meeting: * Pre-treatment with\nNanoprimer followed by administration of LNP-delivered recombinant DNA\n(“LNP-DNA”) designed for anti-tumor immunotherapy showed increased\nsystemic bioavailability, reduced hepatic toxicity, and reduced cGAS-STING\nrelated inflammation compared to LNP-DNA administered without the Nanoprimer\nFirst Quarter Financial Updates\n\nCash and Cash Equivalents: The Company believes that the net proceeds from the\nrecent follow-on offering, together with its cash and cash equivalents of\n€42.1 million as of March 31, 2026, will be sufficient to meet its working\ncapital requirements for operations into 2029, consistent with the Company’s\ncurrently contemplated cash burn rate.\n\nAbout JNJ-1900 (NBTXR3)\n\nJNJ-1900 (NBTXR3) is a novel, potentially first-in-class oncology product\ncomposed of functionalized hafnium oxide nanoparticles that is administered\nvia one-time intratumoral injection and activated by radiotherapy. Its\nproof-of-concept was achieved in soft tissue sarcomas through a successful\nrandomized Phase 2/3 study in 2018. The product candidate’s mechanism of\naction (MoA) is designed to induce significant tumor cell death in the\ninjected tumor when activated by radiotherapy, subsequently triggering\nadaptive immune response and long-term anti-cancer memory. Given the physical\nMoA, Nanobiotix believes that JNJ-1900 (NBTXR3) could be scalable across any\nsolid tumor that can be treated with radiotherapy and across any therapeutic\ncombination, particularly immune checkpoint inhibitors.\n\nRadiotherapy-activated JNJ-1900 (NBTXR3) is being evaluated across multiple\nsolid tumor indications as a single agent or combination therapy. The program\nis led by NANORAY-312—a global, randomized Phase 3 study in locally advanced\nhead and neck squamous cell cancers. In February 2020, the United States Food\nand Drug Administration granted regulatory Fast Track designation for the\ninvestigation of JNJ-1900 (NBTXR3) activated by radiation therapy, with or\nwithout cetuximab, for the treatment of patients with locally advanced HNSCC\nwho are not eligible for platinum-based chemotherapy—the same population\nbeing evaluated in the Phase 3 study.\n\nGiven the Company’s focus areas, and balanced against the scalable potential\nof NBTXR3, Nanobiotix has engaged in a collaboration strategy to expand\ndevelopment of the product candidate in parallel with its priority development\npathways. Pursuant to this strategy, in 2019 Nanobiotix entered into a broad,\ncomprehensive clinical research collaboration with The University of Texas MD\nAnderson Cancer Center to sponsor several Phase 1 and Phase 2 studies\nevaluating JNJ-1900 (NBTXR3) across tumor types and therapeutic combinations.\nIn 2023, Nanobiotix announced a license agreement for the global\nco-development and commercialization of JNJ-1900 (NBTXR3) with Janssen\nPharmaceutica NV, a Johnson & Johnson company.\n\nAbout NANOBIOTIX\n\nNanobiotix is a late-stage clinical biotechnology company pioneering\ndisruptive, physics-based therapeutic approaches to revolutionize treatment\noutcomes for millions of patients; supported by people committed to making a\ndifference for humanity. The Company’s philosophy is rooted in the concept\nof pushing past the boundaries of what is known to expand possibilities for\nhuman life.\n\nIncorporated in 2003, Nanobiotix is headquartered in Paris, France and is\nlisted on Euronext Paris since 2012 and on the Nasdaq Global Select Market in\nNew York City since December 2020. The Company has subsidiaries in Cambridge,\nMassachusetts (United States) amongst other locations.\n\nNanobiotix is the owner of more than 30 umbrella patents associated with three\n(3) nanotechnology platforms with applications in 1) oncology; 2)\nbioavailability and biodistribution; and 3) disorders of the central nervous\nsystem.\n\nFor more information about Nanobiotix, visit us at www.nanobiotix.com or\nfollow us on LinkedIn and Twitter.\n\nDisclaimer\n\nThis press release contains “forward-looking” statements within the\nmeaning of the “safe harbor” provisions of the Private Securities\nLitigation Reform Act of 1995, including, but not limited to, statements\nregarding the use of proceed therefrom, and the period of time through which\nthe Company’s anticipates its financial resources will be adequate to\nsupport operations. Words such as “expects”, “intends”, “can”,\n“could”, “may”, “might”, “plan”, “potential”, “should”\nand “will” or the negative of these and similar expressions are intended\nto identify forward-looking statements. These forward-looking statements which\nare based on the Company’ management’s current expectations and\nassumptions and on information currently available to management. These\nforward-looking statements involve known and unknown risks, uncertainties and\nother factors that could cause actual results to differ materially from those\nimplied by the forward-looking statements, including risks related to\nNanobiotix’s business and financial performance, which include the risk that\nassumptions underlying the Company’s cash runway projections are not\nrealized. Further information on the risk factors that may affect company\nbusiness and financial performance is included in Nanobiotix’s Annual Report\non Form 20-F filed with the SEC on March 31, 2026 under “Item 3.D. Risk\nFactors”, in Nanobiotix’s 2025 universal registration document filed with\nthe AMF on March 31, 2026 under “chapter 1.5 Risk Factors”, and subsequent\nfilings Nanobiotix makes with the SEC and AMF from time to time, which are\navailable on the SEC’s website at www.sec.gov and on the AMF's website at\nwww.amf.org, The forward-looking statements included in this press release\nspeak only as of the date of this press release, and except as required by\nlaw, Nanobiotix assumes no obligation to update these forward-looking\nstatements publicly.\n\n Nanobiotix                                                                                                                                                                                                                                                                                                              \n Communications Department Brandon Owens VP, Communications +1 (617) 852-4835 contact@nanobiotix.com  Investor Relations Department Joanne Choi VP, Investor Relations (US) +1 (713) 609-3150 joanne.choi@nanobiotix.com  Ricky Bhajun Director, Investor Relations (EU) +33 (0) 79 97 29 99 investors@nanobiotix.com    \n Media Relations                                                                                                                                                                                                                                                                                                         \n France – HARDY Caroline Hardy +33 06 70 33 49 50 carolinehardy@outlook.fr                            Global – uncapped Becky Lauer +1 (646) 286-0057 uncappednanobiotix@uncappedcommunications.com                                                                                                                      \n                                                                                                                                                                                                                                                                                                                         \n\n(__________________________1) Antonia SJ, et al. N Engl J Med. 2017.\n\nAttachment\n*     2026-06-02 -- NBTX -- 1Q26 Financial Results -- FINAL\n(https://ml.globenewswire.com/Resource/Download/9b445891-f837-499e-b743-ee1303bca1a5)\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/36fb7b98-27d7-46cb-b989-fa31626657b8)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-06-02T20:30:00.303350109Z","server_sent_at_ms":1780432200303},"received_at":"2026-06-02T20:30:00.602Z","source_url":null},"analysis":{"id":"42359","press_release_id":"52928","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"operations_update","narrative":"Nanobiotix completed a €86.1 million follow-on offering in May 2026, which, combined with its existing €42.1 million cash balance, extends its operational runway into 2029.\n\nThe company presented positive Part 1 data from the J&J-sponsored Phase 2 CONVERGE study for JNJ-1900 in Stage 3 NSCLC, reporting an 85.7% overall response rate and 57.1% complete response rate in a small cohort of 7 patients.\n\nAdditionally, the FDA accepted a protocol amendment for the pivotal Phase 3 NANORAY-312 study, eliminating the interim analysis and allowing for a sooner final analysis with fewer events, accelerating the path to readout.","sentiment":"bullish","agentHooks":{"shouldPost":true,"suggestedAngle":"Nanobiotix secures €86M raise to fund operations through 2029, backed by promising early NSCLC data and accelerated Phase 3 timeline."},"keyFigures":{"customDimensions":{"orr_elcc":"71.4%","crr_estro":"57.1%","orr_estro":"85.7%","cash_runway":"into 2029","offering_proceeds":"€86.1 million","cash_and_equivalents":"€42.1 million"}},"quotedText":"Nanobiotix continues to advance with focus, discipline, and ambition as we work to unlock the full potential of physics-based nanotherapeutics","namedEntities":{"people":[{"name":"Laurent Levy","role":"CEO"},{"name":"Brandon Owens","role":"VP, Communications"},{"name":"Joanne Choi","role":"VP, Investor Relations (US)"},{"name":"Ricky Bhajun","role":"Director, Investor Relations (EU)"}],"products":["JNJ-1900","NBTXR3","Nanoprimer","durvalumab"],"companies":[{"name":"Nanobiotix","ticker":"NBTX","relationship":"filer"},{"name":"Johnson & Johnson","ticker":"JNJ","relationship":"partner"},{"name":"Janssen Pharmaceutica NV","relationship":"partner"},{"name":"The University of Texas MD Anderson Cancer Center","relationship":"collaborator"}],"dollarAmounts":[{"amount":"€86.1 million","context":"gross proceeds from follow-on offering"},{"amount":"€42.1 million","context":"cash and cash equivalents as of March 31, 2026"}]},"materialImpact":{"score":4,"reasoning":"The company secured €86.1M in fresh capital, extending its cash runway to 2029. This is coupled with positive early clinical data (85.7% ORR) for its lead asset JNJ-1900 and a favorable protocol amendment for its pivotal Phase 3 study, de-risking the near-term development path."},"tickerRelevance":{"others":[{"ticker":"NBTX","relevance":"primary listing (NASDAQ)"},{"ticker":"JNJ","relevance":"partner"}],"primary":"NANOB"},"globalImportance":45,"audienceRelevance":35,"eventTypeSecondary":["offering","clinical_trial"],"importanceComponents":{"tickerTier":"mid-cap","eventGravity":"capital_raise + clinical_data","sectorWeight":"high","householdBrandBoost":"low","marketCapAdjustment":"neutral","retailFavoriteBoost":"low"}},"event_type":"operations_update","event_type_secondary":["offering","clinical_trial"],"sentiment":"bullish","material_impact_score":4,"narrative":"Nanobiotix completed a €86.1 million follow-on offering in May 2026, which, combined with its existing €42.1 million cash balance, extends its operational runway into 2029.\n\nThe company presented positive Part 1 data from the J&J-sponsored Phase 2 CONVERGE study for JNJ-1900 in Stage 3 NSCLC, reporting an 85.7% overall response rate and 57.1% complete response rate in a small cohort of 7 patients.\n\nAdditionally, the FDA accepted a protocol amendment for the pivotal Phase 3 NANORAY-312 study, eliminating the interim analysis and allowing for a sooner final analysis with fewer events, accelerating the path to readout.","key_figures":{"customDimensions":{"orr_elcc":"71.4%","crr_estro":"57.1%","orr_estro":"85.7%","cash_runway":"into 2029","offering_proceeds":"€86.1 million","cash_and_equivalents":"€42.1 million"}},"named_entities":{"people":[{"name":"Laurent Levy","role":"CEO"},{"name":"Brandon Owens","role":"VP, Communications"},{"name":"Joanne Choi","role":"VP, Investor Relations (US)"},{"name":"Ricky Bhajun","role":"Director, Investor Relations (EU)"}],"products":["JNJ-1900","NBTXR3","Nanoprimer","durvalumab"],"companies":[{"name":"Nanobiotix","ticker":"NBTX","relationship":"filer"},{"name":"Johnson & Johnson","ticker":"JNJ","relationship":"partner"},{"name":"Janssen Pharmaceutica NV","relationship":"partner"},{"name":"The University of Texas MD Anderson Cancer Center","relationship":"collaborator"}],"dollarAmounts":[{"amount":"€86.1 million","context":"gross proceeds from follow-on offering"},{"amount":"€42.1 million","context":"cash and cash equivalents as of March 31, 2026"}]},"model_name":"qwen3_6_27b_awq","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-06-02T20:32:39.079Z","global_importance":45,"audience_relevance":35,"importance_components":{"tickerTier":"mid-cap","eventGravity":"capital_raise + clinical_data","sectorWeight":"high","householdBrandBoost":"low","marketCapAdjustment":"neutral","retailFavoriteBoost":"low"}},"durationMs":65447,"modelName":"george-droid-qwen-72b"}}